FDA Approval Activities for this Drug…

VIREAD (tenofovir disoproxil fumarate) Tablets, 300 mg, Gilead Sciences, Inc NDA 21-356/S5 10/14/03 10/16/03 10/16/03 VIREAD (tenofovir disoproxil fumarate) Tablets, 300 mg, Gilead Sciences, Inc NDA 21-356/S3 8/15/03 8/28/03 8/28/03 VIREAD (tenofovir disoproxil fumarate) Tablets, 300 mg, Gilead Sciences, Inc NDA 21-356/S1 12/2/02 12/9/02 12/2/02 VIREAD (tenofovir disoproxil fumarate) Tablets, 300 mg Gilead Sciences, Inc NDA 21-356 10/26/01 11/2/01 11/2/01 1/14/02 VIREAD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. VIREAD (tenofovir disoproxil fumerate) 300 mg Tablets, Gilead Sciences, Inc., Labeling Revision Truvada, (emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg)) tablets, Gilead Sciences, Approval | Truvada (emtricitabine/tenofovir DF) Tablets, Gilead Sciences, Labeling Revision

For the latest approval information, please locate this drug using this index.